Log In
Print
BCIQ
Print
Print this Print this
 

Relistor, methylnaltrexone (MNTX) (MOA-728, ONO-3849)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (OPRM1; MOR) antagonist
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in non-cancer patients with chronic pain; Treat opioid-induced constipation (OIC) in patients undergoing orthopedic surgery; Treat opioid-induced constipation (OIC) in patients with chronic pain; Treat postoperative ileus (POI) and constipation
Regulatory Designation

Partner

Ono Pharmaceutical Co. Ltd.; Salix Pharmaceuticals Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today